kabutan

D.Western Therapeutics Institute, Inc.(4576) Summary

4576
TSE Growth
D.Western Therapeutics Institute, Inc.
99
JPY
0
(0.00%)
Mar 16, 9:04 am JST
0.62
USD
Mar 15, 8:04 pm EDT
Result
PTS
outside of trading hours
98.9
Mar 16, 9:03 am JST
Summary Chart Historical News Financial Result
PER
PBR
3.75
Yield
ー%
Margin Trading Ratio
899.63
Stock Price
Mar 16, 2026
Opening Mar 16, 9:00 am
99 JPY 0.62 USD
Previous Close Mar 13
99 JPY 0.62 USD
High Mar 16, 9:00 am
99 JPY 0.62 USD
Low Mar 16, 9:00 am
99 JPY 0.62 USD
Volume
16,200
Trading Value
2.00M JPY 0.01M USD
VWAP
99.0 JPY 0.62 USD
Minimum Trading Value
9,900 JPY 62 USD
Market Cap
5.37B JPY 0.03B USD
Number of Trades
4
Liquidity & Number of Trades
As of Mar 16, 2026
Liquidity
Slightly High
1-Year Average
518
1-Year High Sep 26, 2025
25,219
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 6,120,300
Feb 27, 2026 0 6,129,700
Feb 20, 2026 0 6,336,600
Feb 13, 2026 0 6,778,000
Feb 6, 2026 0 6,933,500
Company Profile
D.Western Therapeutics Institute, Inc. is a drug discovery venture originating from Mie University, focusing on protein kinase inhibitors and developing glaucoma treatments.
Sector
Pharmaceuticals
D.Western Therapeutics Institute, Inc. conducts research and development of pharmaceuticals in the ophthalmology field, primarily centered on protein kinase inhibitors, and operates a drug discovery business that licenses out its developed products to pharmaceutical companies. Their main product, ripasudil hydrochloride hydrate, has been launched in Japan and Asia as a treatment for glaucoma and ocular hypertension, and is also being developed for expanded use in Fuchs' endothelial corneal dystrophy. Additionally, the ophthalmic surgical aid DW-1002 is currently on sale in Europe and the United States, and is under development in Japan. Clinical trials for their in-house developed product H-1337 are also underway. The company has established an efficient research and development system by utilizing their proprietary Drug Western method and actively collaborating with universities and other companies.